India's pharmaceutical industry is entering a new phase of transformation. While traditional generic medicines continue to provide stability, companies are increasingly looking beyond their core businesses to build the next wave of growth through biosimilars, innovation, nutraceuticals, consumer healthcare and contract manufacturing.
Speaking to ET Now, Vishal Manchanda from Systematix Group shared his outlook on the evolving opportunities across the pharmaceutical sector, highlighting where the biggest profit pools could emerge over the next few years.
